Filing Details
- Accession Number:
- 0001209191-24-001155
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-08 16:43:46
- Reporting Period:
- 2023-11-04
- Accepted Time:
- 2024-01-08 16:43:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1664710 | Keros Therapeutics Inc. | KROS | Pharmaceutical Preparations (2834) | 811173868 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1682068 | Keith Regnante | C/O Keros Therapeutics, Inc. 1050 Waltham Street, Suite 302 Lexington MA 02421 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-11-04 | 40,000 | $16.00 | 40,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-11-04 | 40,000 | $45.29 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-01-04 | 40,000 | $0.00 | 40,000 | $16.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 53,622 | 2030-04-06 | No | 4 | M | Direct |
Footnotes
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
- One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Billionaire Hedge Funds
